An important conclusion of our results is that global blockade or inhibition of SPT2, achieved with pharmacological approaches which seek to rescue insulin sensitivity in T2D [9], is likely to be deleterious at the level of the pancreatic β-cell, and thus to suppress insulin production. The gene discussed is SPTLC2; the disease is type 2 diabetes mellitus.